- Home
- RADX vs TPST Comparison
RADX vs TPST Comparison
Compare RADX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- TPST
- Stock Information
- Founded
- RADX 2021
- TPST 2011
- Country
- RADX Australia
- TPST United States
- Employees
- RADX N/A
- TPST N/A
- Industry
- RADX
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- TPST Health Care
- Exchange
- RADX NYSE
- TPST Nasdaq
- Market Cap
- RADX 32.5M
- TPST 33.0M
- IPO Year
- RADX N/A
- TPST N/A
- Fundamental
- Price
- RADX $4.64
- TPST $7.54
- Analyst Decision
- RADX Strong Buy
- TPST Hold
- Analyst Count
- RADX 3
- TPST 3
- Target Price
- RADX $15.00
- TPST $30.00
- AVG Volume (30 Days)
- RADX 17.9K
- TPST 94.0K
- Earning Date
- RADX 02-26-2025
- TPST 08-11-2025
- Dividend Yield
- RADX N/A
- TPST N/A
- EPS Growth
- RADX N/A
- TPST N/A
- EPS
- RADX N/A
- TPST N/A
- Revenue
- RADX $204,609.00
- TPST N/A
- Revenue This Year
- RADX N/A
- TPST N/A
- Revenue Next Year
- RADX N/A
- TPST N/A
- P/E Ratio
- RADX N/A
- TPST N/A
- Revenue Growth
- RADX N/A
- TPST N/A
- 52 Week Low
- RADX $3.50
- TPST $5.35
- 52 Week High
- RADX $50.82
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- TPST 56.78
- Support Level
- RADX N/A
- TPST $7.13
- Resistance Level
- RADX N/A
- TPST $8.75
- Average True Range (ATR)
- RADX 0.00
- TPST 0.47
- MACD
- RADX 0.00
- TPST 0.12
- Stochastic Oscillator
- RADX 0.00
- TPST 54.17
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.